Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Adam on +44 1494 818010 or adam@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Adam Woolley
Recruitment Consultant
adam@zenopa.com
+44 1494 818010

Testimonials
Zenopa was extremely effective during my search for a new sales role. I was very pleased with the types of job role put forward and the consistent number of opportunities that my account manager conti...
Nina, 2013

Novartis hails key regulatory decision for Afinitor

9 May 2011 00:00 in Pharmaceutical Company Product News


Novartis has hailed its success in obtaining US regulatory approval for Afinitor, its everolimus tablet-based treatment for advanced pancreatic neuroendocrine tumours.

The treatment has become the first product to be approved for this specification in the territory for nearly 30 years, with the company having also submitted a marketing application for the drug in this indication to the European Medicines Agency.

Authorisation was granted based on positive data from phase III clinical trials, showing Afinitor's efficacy in reducing tumour growth rates and cancer progression risk.

Everolimus is currently available in the EU under the trade name Certican for non-oncology applications, such as preventing organ rejection after heart and kidney transplants.

Herve Hoppenot, president of Novartis Oncology, said the new approval for the drug shows how effective treatments that target the protein mTOR to inhibit tumour growth can be.

This comes after the company launched Gilenya in the UK last month, with the product representing the first ever oral multiple sclerosis treatment released in Britain.ADNFCR-8000103-ID-800523685-ADNFCR

Other news stories from 09/05/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd